Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sounds good. Seems like the new SBFM IR/PR firm can now leverage the announcement to put SBFM on the map. All they would have to do is say that SBFM is planning to start the mRNA clinical trials at McGill in XX quarter.
Then, they could follow that with a PR that says they are negotiating a relationship with Moderna to speed up SBFM's mRNA cancer drug development.
Just some ideas for SBFM and the new PR firm.
Are SBFM, McGill U, and Moderna now linked together as a strategic alliance?
LATE BREAKING NEWS: Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market
April 26 2022 - 12:41AM
GlobeNewswire Inc
https://ih.advfn.com/stock-market/NASDAQ/sunshine-biopharma-SBFM/stock-news/87903478/sunshine-biopharma-inc-announces-pricing-of-19
ADTM needs a reason to get current and... the only thing I can think of after years of disappointment is this: https://mymedicinebox.com/about.html
Note that Angel (from PlutusX) is now on this team along with John as a Co-Founder.
I don't hold much hope, but do still hold some shares.
GL
NEWS: Coastal Capital Acquisition Corp. ($CCAJ) is Discussing the Possible Acquisition of Advanced Warning Systems
https://world.einnews.com/pr_news/569604669/coastal-capital-is-considering-the-merits-of-acquiring-aws-which-makes-scanners-for-cars-boats-and-other-large-objects
JACKSONVILLE, FLORIDA, UNITED STATES, April 22, 2022/EINPresswire.com/ -- Advanced Warning Systems is the exclusive worldwide marketer of the IGRIS Total Scanning Solution which is a producer of the scanning equipment that can detect most types of explosive materials down to a firecracker. The product made by this entity is a proprietary system that can be used in airports, vehicles and cargo ships. However, they can typically be used in almost any setting in which items are moved from one point to another. They can also be used to detect most other items that a civilian or government client would be interested in detecting including drugs or other contraband smuggled from an international point of view.
$CCAJ's interest in the company is based primarily on its ability to achieve outsized revenue growth over the next several years. In addition, the overall value of the company is boosted by the presence of intellectual property rights that can be leveraged in a profitable manner in the future.
In an interconnected economy, it's not uncommon for millions of pounds of goods to flow through land and water checkpoints each day. If a shipment is compromised in any way, it could result in significant loss of life as well as a significant disruption to local and regional economies. It can also result in prolonged supply chain issues that may cause price instability and other issues.
However, the products produced by Dr. Wayne Jones can make it harder for terrorists or other criminals to move explosive materials through airports or through ports. If the Inelastic Gamma Ray Imaging System (IGRIS - [E-GRIS]) Total Scanning Solution finds anything that it deems to be suspicious, it will create a report and send it to a Law Enforcement for review.
Dr. Jones has spent over 35 years with a primary focus on neutron scanning for detection of contraband, explosives, and items of interest to Customs. Dr. Wayne Jones is a Nuclear Scientist with an expansive history including working with the US Military.
The IGRIS system uses computers and other advanced tools that can reliably determine the atomic structure of almost any object. As the computer is the one determining what is inside of a given container, it minimizes the risk of a human confusing a dangerous substance with something that is more benign. Furthermore, scans can be done in an autonomous manner, which can make a facility safer without necessarily increasing security or labor costs.
As the IGRIS system can spot items that may be subject to customs fees, governments may be able to minimize losses related to customs evasion. Any money that is recovered by a government agency may be put to use further enhancing security at land, air or sea checkpoints.
Just imagine a world that has less stress of the turmoil that terrorism brings to humanity, this product is one that can curve and start the process to eliminate those threats. On their website, AWS shows the process of how the IGRIS system works.
One of the reasons why AWS is such an attractive merger or takeover target is that it has been around since the 1970s. Combined, its core leadership team has hundreds of years of experience in both the scientific and corporate fields.
Of course, it's important to note that there are no formal plans at this time to enter into negotiations but discussions between $CCAJ and AWS has taken place. If Coastal Capital and AWS determines that it makes sense to do so from a financial and logistical perspective. If negotiations do begin, investors and others will be notified about the state of those talks, and investors will also be notified if an actual merger takes place.
Coastal Capital invests in almost any company that shows a potential to achieve high rates of return on Coastal's capital.
Investor Relations Department
Coastal Capital Acquisition Corp.
+1 888-241-7333
email us here
Visit us on social media:
Twitter
LinkedIn
Was it this SBFM News that came out at 6:45pm today:
https://marketwirenews.com/news-releases/blockbuster-clinical-results-shine-a-positive-light--7652719222137293.html
Maybe we hear more on SBFM Clinical Trials at McGill U/Jewish General Hospital/Lady Davis Institute for Medical Research.
The Lady Davis Institute (LDI) is the research arm of Montreal's Jewish General Hospital, a teaching hospital of McGill University. It is among Canada’s leading medical research institutions. Major fields of inquiry include cancer, hemovascular diseases, epidemiology, diseases of aging, HIV/AIDS, and psychosocial science. Important discoveries made at the LDI have contributed to the health and well-being of patients in Quebec, Canada, and around the world since its founding in 1969.
https://www.jgh.ca/research/lady-davis-institute-for-medical-research-ldi/
http://www.ladydavis.ca/
Thanks. I missed that date and don't knowingly post outdated articles. I'll do better next time!
This looks like the place where SBFM will do clinical trials for pancreatic cancer:
See link below and the The Saltikva Study as an example of their cancer research.
http://www.ladydavis.ca/
Sunshine Biopharma Looking to Mimic Roche’s Billion-Dollar Cancer Drug
Last year, over 260,000 new cases of breast cancer (invasive and in situ combined) were diagnosed in women in the US. Over the course of a woman’s lifetime, the odds are greater than 12% (or 1 out of every 8) that she will develop invasive breast cancer and have only about a 41% chance of surviving for 5 years if not detected until stage IIIB (odds are increased to approximately 90% if caught in stage I). Although most people don’t consider it, men aren’t removed from invasive breast cancer stats either; nearly 2,000 new cases were diagnosed in 2010 as well.
Given the high death rate for late-stage detection (odds slip all the way to a meager 15% chance of living 5 more years when detected in stage 4), there is a huge area of unmet need for new therapies to treat the disease. One company looking to make a dent in the number of breast cancer deaths is Montreal, Canada-based Sunshine Biopharma, Inc., a drug maker engaged in researching and developing drugs for a wide array of cancers with their initial focus on breast cancer.
Sunshine is taking the path less traveled by attacking drug-resistant cancers, a course of action that can be difficult, but reap impressive rewards if successful and Sunshine is showing promising results to date. The company’s flagship compound in development is Adva-27, a small molecule that targets and inhibits Topoisomerase II (Top2), an enzyme found in abundance in various types of aggressive carcinomas. It is widely known that there are two genes associated with aggressive forms of cancer: Her2 (human epidermal growth factor receptor-2) and Top2. Swiss drug maker Roche’s Herceptin (Trastuzumab) is an effective treatment for Her2-positive patients. Showcasing the magnitude of usage for a viable indication addressing one of the genes, Herceptin generated roughly $7 billion in global sales for Roche in 2010.
Recently, Sunshine announced it has completed a detailed cytotoxicity study, a measure of a drug’s ability to destroy cancer cells in vitro, of Adva-27a, in MCF-7/MDR, a multidrug-resistant breast cancer cell line. According to the company, the study’s results showed that Adva-27a is 16-times more effective at killing multidrug-resistant breast cancer cells than Etoposide, a current commonly used drug. In addition, data generated by the study revealed that Adva-27a is unaffected by the molecular machinery that are responsible for making cancer cells resistant to drugs. Multidrug resistance is a major component in the failure of many of today’s chemotherapies, so drugs that show the ability to thwart the resistance factor are heralded as particularly valuable from both a humanitarian and financial standpoint.
The life span of a biotech stock play runs in cycles with one area of common upward price movement being the commencement of clinical trials. Sunshine is nearing that milestone with McGill University’s The Jewish General Hospital already agreeing to host the Phase I clinical trials. A thinly traded stock with a paltry market cap of under $30 million, biotech investors will be on the lookout for news of the human trials and any further cancer drug development news that could be the catalyst required to drive the share value to the next level.
Total Page Views: 5126
https://drug-dev.com/sunshine-biopharma-looking-to-mimic-roches-billion-dollar-cancer-drug/
FDA Accelerated Approval Process....I assume SBFM is looking at this now....
Accelerated Approval
In some cases, the approval of a new drug is expedited. Accelerated Approval can be applied to promising therapies that treat a serious or life-threatening condition and provide therapeutic benefit over available therapies. This approach allows for the approval of a drug that demonstrates an effect on a “surrogate endpoint” that is reasonably likely to predict clinical benefit, or on a clinical endpoint that occurs earlier but may not be as robust as the standard endpoint used for approval. This approval pathway is especially useful when the drug is meant to treat a disease whose course is long, and an extended period of time is needed to measure its effect. After the drug enters the market, the drug maker is required to conduct post-marketing clinical trials to verify and describe the drug’s benefit. If further trials fail to verify the predicted clinical benefit, FDA may withdraw approval.
Since the Accelerated Approval pathway was established in 1992, many drugs that treat life-threatening diseases have successfully been brought to market this way and have made a significant impact on disease course. For example, many antiretroviral drugs used to treat HIV/AIDS entered the market via accelerated approval, and subsequently altered the treatment paradigm. A number of targeted cancer-fighting drugs also have come onto the market through this pathway.
More information on Accelerated Approval is here: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval
Drug Development Designations
The agency also employs several approaches to encourage the development of certain drugs, especially drugs that may represent the first available treatment for an illness, or ones that have a significant benefit over existing drugs. These approaches, or designations, are meant to address specific needs, and a new drug application may receive more than one designation, if applicable. Each designation helps ensure that therapies for serious conditions are made available to patients as soon as reviewers can conclude that their benefits justify their risks.
Fast Track is a process designed to facilitate the development and advance the review of drugs that treat serious conditions, and fill an unmet medical need, based on promising animal or human data. Fast tracking can get important new drugs to the patient earlier. The drug company must request the Fast Track process. More information about the Fast Track process is here: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
Breakthrough Therapy designation expedites the development and review of drugs that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy. A drug with Breakthrough Therapy designation is also eligible for the Fast Track process. The drug company must request a Breakthrough Therapy designation. More information about Breakthrough Therapy designation is here: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
Priority Review means that FDA aims to take action on an application within six months, compared to 10 months under standard review. A Priority Review designation directs attention and resources to evaluate drugs that would significantly improve the treatment, diagnosis, or prevention of serious conditions. More information about Priority Review is here: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review
Most likely SBFM was working on patent paperwork already when that announcement was made. Could be that they have applied by now.
And close between $6-10?
Ok, and if the air is clear now, SBFM should move back up to $8+ I would assume.
Did they have to put out a PR to "confirm the S3 resale went into effect?" Is that a NAS requirement or some other requirement?
SBFM @ $11+ afterhours on Thursday was the biggest surprise to me last week. Perhaps that was an indicator of where SBFM is headed next week.
The days/weeks/months ahead will be bumpy and exciting for those holding now and those buying.
What is your expectation/speculation for the coming week?
Looks like Dr. Slilaty is circling back to his Alma Mater to finish development of the Covid-19 pill: "Dr. Slilaty is an accomplished scientist and a highly skilled business executive. He received his Bachelor of Science degree in Genetics and Biochemistry from Cornell University and his Ph.D. in Molecular Biology & Biochemistry from the University of Arizona."
Also, his new colleague (Dr. Gregory Thatcher), who is now at the UoA, got his degree at the University of Toronto, Canada so maybe they will now close the deal!
Education & Post Graduate Training:
PhD, University of Toronto, Canada, 1986
BSc, University of Manchester, UK, 1981
Research Associate, University of Sheffield, UK, 1986
Research Fellow, Oxford University, UK, 1988
https://www.pharmacy.arizona.edu/directory/profile/gregory-thatcher-phd
I've been wondering why they linked up with UoA.
Wake me up at $30. I want to watch the climb to $360!
Looks like IR and PR. See Sunshine FAQs on this page of their website. There is also a PDF presentation.
https://investors.sunshinebiopharma.com/
I will smile if we see $30 soon...I'll smile again at $60, then $120 and so on!
Are they merging...similar logos and business....http://www.pantheraholdings.ch/from-our-ceo.html
CCAJ Twitter Account started posting March 3.... https://twitter.com/ccajstock
This looks new: https://buyessential9.com/ .........
But will it help move SBFM higher?
Perhaps somewhere between $.06-.10
From $.0003 to .0075 = 2500% gain in 2021 (assuming I did my math right). That does not seem like a "real disaster"!
And added a registered domain: ccajstock.com
I don't know much about OASIS? Do you have any info? I did a quick search and found this, but not sure if related: https://oasis-living.com/
I know AXXA does a lot of business in Europe and likes property and technology. Maybe this is related, but not sure.
Is AXXA on a path to $100M Revenue and $330M Assets over the next year or so?
If that is accurate I'll be on the path to buying more soon!
Is it time for a 6 month hibernation? Then wake up and see $$$$$?
Anyone got a 6 month PPS projection?
That's what I thought, a Massive update! Forgot where I read it.
Is 1MYLE on deck this week for a PR?
New COVID variant named Omicron..."The World Health Organization announced Friday that it has designated the newly identified coronavirus variant, B.1.1.529, as a variant of concern, named Omicron."
My assumption is that SBFM will address this new VoC in terms of SBFM's COVID pill's ability to address this variant. Hopefully they also update progress of getting it reviewed by the FDA as an Investigational New Drug (IND).
Is it political or a real concern...the reality is that COVID makes people sick and kills people so getting both vaccine and treatment options quickly is needed to keep economies functioning. In the meantime economies will suffer longer and travel restrictions are already increasing again (see below). SBFM has been very quiet on the COVID pill, so they need to get some info out about how far along they are to help fight the battle with COVID.
"The European Union and other major destinations have moved to block flights from African countries following the discovery of an aggressive mutation of the Covid-19 virus, echoing previous emergency responses that triggered a global freeze on travel. Italy, Austria, France, Germany, Japan and the the UK are among those imposing restrictions on flights and travelers from six African nations after the new strain, known as B.1.1.529 variant, was detected in South Africa, Botswana, and in two travelers quarantining in Hong Kong. A case has also been reported in Belgium."
More on the future of COVID-19 and need for more treatment options...SBFM needs to pick up the pace! See link below...
https://www.cnn.com/2021/11/25/world/covid-variant-south-africa-immune-evasion-transmissibility/index.html
Yes, just waiting for the 1MYLE CRYPTO blast-off and New Massive Deal PR!
Exxegroup @exxegroup Oct 27
$AXXA Next Catalysts
* Results for the Q is due in a just over 2 weeks
* #1Myle #Crypto #Swap update after upgrades
* #New #Massive #Deal #PR & its integration with #digital #strategy
* #MMC #DigitalMarketing is getting setup. We'll push it in November on multiple media channels
I know SBFM has science. We just need to know that the FDA likes their science. Once that occurs it's off to the Races or to the Moon or wherever Sunshine takes us!
AXXA Banner Ads showing up on Investorshub also!
Starting to see AXXA ads from AdChoices on the homepages of various websites. Saw it tonight on the right side of https://www.yahoo.com/
Looks like the media marketing campaign has begun!
Finally read 10-Q. Looks like AEGIS is the make or break deal SBFM needs. If successful the deal will mitigate SBFM's money woes. If not, then who knows what happens. Looking forward to an AEGIS update!